Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 45 Records) |
| Query Trace: Neoplasms and HGF[original query] |
|---|
| A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903). Lung cancer (Amsterdam, Netherlands) 2014 Nov 86 (2): 195-200. Matsumoto Yoshifumi, Maemondo Makoto, Ishii Yoshiki, Okudera Koichi, Demura Yoshiki, Takamura Kei, Kobayashi Kunihiko, Morikawa Naoto, Gemma Akihiko, Ishimoto Osamu, Usui Kazuhiro, Harada Masao, Miura Satoru, Fujita Yuka, Sato Ikuro, Saijo Yasuo, |
| The associations between immunity-related genes and breast cancer prognosis in Korean women. PloS one 2014 9 (7): e103593. Choi Jaesung, Song Nan, Han Sohee, Chung Seokang, Sung Hyuna, Lee Ji-young, Jung Sunjae, Park Sue K, Yoo Keun-Young, Han Wonshik, Lee Jong Won, Noh Dong-Young, Kang Daehee, Choi Ji-Ye |
| Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation. Molecular and clinical oncology 2015 Mar 3 (2): 329-333. Oikawa Takefumi, Ohira Tatsuo, Otani Keishi, Hagiwara Masaru, Konaka Chimori, Ikeda Norihi |
| Clinical impact of c-MET expression and mutational status in patients with colorectal cancer lung metastases. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2015 Oct . Schweiger Thomas, Starkl Veronika, Glueck Olaf, Glogner Christoph, Traxler Denise, Jedamzik Julia, Liebmann-Reindl Sandra, Birner Peter, Streubel Berthold, Klepetko Walter, Hoetzenecker Konr |
| Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget 2015 1 6 (5): 2604-14. Liu Shuying, Meric-Bernstam Funda, Parinyanitikul Napa, Wang Bailiang, Eterovic Agda K, Zheng Xiaofeng, Gagea Mihai, Chavez-MacGregor Mariana, Ueno Naoto T, Lei Xiudong, Zhou Wanding, Nair Lakshmy, Tripathy Debu, Brown Powel H, Hortobagyi Gabriel N, Chen Ken, Mendelsohn John, Mills Gordon B, Gonzalez-Angulo Ana |
| Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib. ESMO open 2016 1 (4): e000063. Azuma Koichi, Hirashima Tomonori, Yamamoto Nobuyuki, Okamoto Isamu, Takahashi Toshiaki, Nishio Makoto, Hirata Taizo, Kubota Kaoru, Kasahara Kazuo, Hida Toyoaki, Yoshioka Hiroshige, Nakanishi Kaoru, Akinaga Shiro, Nishio Kazuto, Mitsudomi Tetsuya, Nakagawa Kazuhi |
| Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma. Medical science monitor : international medical journal of experimental and clinical research 2016 22 276-83. He Yayi, Wang Yan, Boyle Theresa, Ren Shengxiang, Chan Dan, Rivard Chris, Li Xuefei, Li Jiayu, Zhou Caicun, Hirsch Fred |
| Tracking MET de-addiction in lung cancer: A road towards the oncogenic target. Cancer treatment reviews 2017 8 60 1-11. Pilotto S, Carbognin L, Karachaliou N, Ma P C, Rosell R, Tortora G, Bria |
| Plasma T790M and HGF as potential predictive markers for EGFR-TKI re-challenge. Oncology letters 2017 Jun 13 (6): 4939-4946. Nakamura Tomomi, Watanabe Naomi, Sato Akemi, Komiya Kazutoshi, Umeguchi Hitomi, Hosomi Toshiya, Hirai Mitsuharu, Sueoka Eisaburo, Kimura Shinya, Sueoka-Aragane Nao |
| Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer 2017 Aug 123 (15): 2936-2944. Tarhini Ahmad A, Rafique Imran, Floros Theofanis, Tran Phu, Gooding William E, Villaruz Liza C, Burns Timothy F, Friedland David M, Petro Daniel P, Farooqui Mariya, Gomez-Garcia Jose, Gaither-Davis Autumn, Dacic Sanja, Argiris Athanassios, Socinski Mark A, Stabile Laura P, Siegfried Jill |
| Effects of HGF gene polymorphisms and protein expression on transhepatic arterial chemotherapeutic embolism efficacy and prognosis in patients with primary liver cancer. OncoTargets and therapy 2017 10 803-810. Chen Hai-Yong, Chen Yao-Min, Wu Jian, Yang Fu-Chun, Lv Zhen, Qian Yi-Gang, Zheng Shu-S |
| Concurrent MET copy number gain and KRAS mutation is a poor prognostic factor in pancreatobiliary subtype ampullary cancers. Pathology, research and practice 2017 Jan . Kwon Mi Jung, Kim Jeong Won, Jeon Jang Yong, Nam Eun Sook, Cho Seong Jin, Park Hye-Rim, Min Soo Kee, Seo Jinwon, Min Kyueng-Whan, Choe Ji-Young, Lee Hye Kyu |
| HGF-mediated crosstalk between cancer-associated fibroblasts and MET-unamplified gastric cancer cells activates coordinated tumorigenesis and metastasis. Cell death & disease 2018 8 9 (9): 867. Ding Xusheng, Ji Jun, Jiang Jinling, Cai Qu, Wang Chao, Shi Min, Yu Yingyan, Zhu Zhenggang, Zhang J |
| Interleukin enhancer binding factor 2 is a prognostic biomarker for breast cancer that also predicts neoadjuvant chemotherapy responses. American journal of translational research 2018 10 (6): 1677-1689. Jin Zining, Xu Lu, Zhang Lei, Zhao Min, Li Dongbao, Ye Lijun, Ma Ying, Ren Siyu, Yu Hailan, Wang Danyu, Liang Chunyan, Chen |
| Secretion of high amounts of hepatocyte growth factor is a characteristic feature of cancer-associated fibroblasts with EGFR-TKI resistance-promoting phenotype: A study of 18 cases of cancer-associated fibroblasts. Pathology international 2019 7 69 (8): 472-480. Suzuki Erika, Yamazaki Shota, Naito Tomoyuki, Hashimoto Hiroko, Okubo Satoshi, Udagawa Hibiki, Goto Koichi, Tsuboi Masahiro, Ochiai Atsushi, Ishii Genichi |
| The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies. Molecules (Basel, Switzerland) 2019 12 24 (24): . Van Der Steen Nele, Zwaenepoel Karen, Mazzaschi Giulia, A Luirink Rosa, P Geerke Daan, Op de Beeck Ken, Hermans Christophe, Tiseo Marcello, Van Schil Paul, Lardon Filip, Germonpré Paul, Rolfo Christian, Giovannetti Elisa, J Peters Godefridus, Pauwels Patri |
| Concomitant Mutations in EGFR 19Del/L858R Mutation and Their Association with Response to EGFR-TKIs in NSCLC Patients. Cancer management and research 2020 9 12 8653-8662. Liang Hengrui, Li Caichen, Zhao Yi, Zhao Shen, Huang Jun, Cai Xiuyu, Cheng Bo, Xiong Shan, Li Jianfu, Wang Wei, Zhu Changbin, Li Weiwei, He Jianxing, Liang Wenh |
| [Progress on Mechanism of MET Gene Mutation and Targeted Drugs in Non-small Cell Lung Cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2020 7 23 (7): 609-614. Han Sen, Ma Xu, Fang Ji |
| Mendelian randomisation analysis of circulating adipokines and C-reactive protein on breast cancer risk. International journal of cancer 2020 Mar . Robinson Timothy, Martin Richard M, Yarmolinsky Jam |
| c-Met expression in renal cell carcinoma with bone metastases. Journal of bone oncology 2020 10 25 100315. Silva Paiva Rita, Gomes Inês, Casimiro Sandra, Fernandes Isabel, Costa Lu |
| Identification of New Therapeutic Targets for Gastric Cancer With Bioinformatics. Frontiers in genetics 2020 10 11 865. Li Yang, Wang Jin-Shen, Zhang Tao, Wang Hong-Chang, Li Le-Pi |
| Transcriptomic landscape of early age onset of colorectal cancer identifies novel genes and pathways in Indian CRC patients. Scientific reports 2021 Jun 11 (1): 11765. Singh Manish Pratap, Rai Sandhya, Singh Nand K, Srivastava Same |
| Effect of MACC1 Genetic Polymorphisms and Environmental Risk Factors in the Occurrence of Oral Squamous Cell Carcinoma. Journal of personalized medicine 2021 May 11 (6): . Hu Rei-Hsing, Chuang Chun-Yi, Lin Chiao-Wen, Su Shih-Chi, Chang Lun-Ching, Wu Ssu-Wei, Liu Yu-Fan, Yang Shun- |
| Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study. Lung cancer (Amsterdam, Netherlands) 2021 12 163 7-13. Tan D S-W, Thomas M, Kim D-W, Szpakowski S, Urban P, Mehra R, Chow L Q M, Sharma S, Solomon B J, Felip E, Camidge D R, Vansteenkiste J, Petruzzelli L, Pantano S, Shaw A |
| MET?14 promotes a ligand-dependent, AKT-driven invasive growth. Life science alliance 2022 5 5 (10): . Cerqua Marina, Botti Orsola, Arigoni Maddalena, Gioelli Noemi, Serini Guido, Calogero Raffaele, Boccaccio Carla, Comoglio Paolo M, Altintas Dogus |
| The Expression Quantitative Trait Loci in Immune Response Genes Impact the Characteristics and Survival of Colorectal Cancer. Diagnostics (Basel, Switzerland) 2022 2 12 (2): . Chan Ren-Hao, Chen Po-Chuan, Yeh Yu-Min, Lin Bo-Wen, Yang Kai-Di, Shen Meng-Ru, Lin Peng-Ch |
| Exploration of molecular markers related to chemotherapy efficacy of hepatoid adenocarcinoma of the stomach. Cellular oncology (Dordrecht) 2023 11 . Jingtao Wei, Ke Ji, Yue Zhang, Ji Zhang, Xiaojiang Wu, Xin Ji, Kai Zhou, Xuesong Yang, Hongfeng Lu, Anqiang Wang, Zhaode |
| The impacts of MACC1 gene polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic characteristics in Taiwan. Journal of Cancer 2023 11 14 (18): 3532-3538. Li-Wen Chang, Sheng-Chun Hung, Ying-Erh Chou, Chuan-Shu Chen, Jian-Ri Li, Chia-Yen Lin, Shian-Shiang Wang, Shun-Fa Ya |
| Altered profiles of circulating cytokines in chronic liver diseases (NAFLD/HCC): Impact of the PNPLA3I148M risk allele. Hepatology communications 2023 11 7 (12): . Mélanie Kirchmeyer, Anthoula Gaigneaux, Florence A Servais, Anita Arslanow, Markus Casper, Marcin Krawczyk, Frank Lammert, Iris Behrma |
| Integration of QTL and comprehensive analysis in the circulating inflammatory cytokines for pan-cancer. BMC cancer 2024 8 24 (1): 1007. Haishan Lin, Bangwei C |
- Page last reviewed:Feb 1, 2024
- Content source: